This page shows the latest Ionis Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.
GlaxoSmithKline has announced positive results from a phase 2a study of its Ionis-partnered antisense medicine for chronic hepatitis B virus (CHB) infection. ... As part of the licensing deal, Ionis is set to receive fees and milestone payments of up to
FDA surprises Akcea and Ionis with rejection of Waylivra. Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, has been knocked back by a surprise rejection via a Complete Response Letter (CRL) from ... However Ionis faces stiff competition from
Alnylam's success in the phase III trial proved to be a dampener for Ionis Pharmaceuticals, which is developing antisense-based drug inotersen for this type of familial amyloid polyneuropathy (FAP). ... The company shares fell yesterday on the APOLLO
But Ionis Pharmaceuticals' subsidiary presses on with filing plans. Akcea Therapeutics says it plans to file for approval of its drug for rare disease familial chylomicronaemia syndrome (FCS) later this year ... There was also a reduction in pancreatitis
The jury in the lawsuit upheld Merck's claim that Gilead's sofosbuvir - which features in its massive-selling Sovaldi and Harvoni HCV drugs - infringes two patents it holds alongside Ionis ... Pharmaceuticals (formerly known as Isis Pharma).
Says the move should avoid any 'distraction' to its business. Isis has announced a change in name to Ionis Pharmaceuticals in a bid to avoid any association with the Islamic State ... Ionis "is an original name that the company has chosen to represent
More from news
Approximately 1 fully matching, plus 5 partially matching documents found.
The big biotech is testing its own BIIB092 in early Alzheimer’s patients and has an option to develop an Ionis Pharmaceuticals’ antisense drug designed to reduce production of tau in ... Meanwhile, Karuna Pharmaceuticals has raised $42m to resurrect
Tregs) while preserving effector T‐cells (Teffs). Acquisition. $759m. Ionis Pharmaceuticals/. Roche. ... US. US and Canada only. # US and EU. Roche’s collaboration with Ionis Pharmaceuticals has a headline of $760m, $1m more than the Tusk deal.
Ionis Pharmaceuticals and Bayer entered into a licence in May 2015 for IONIS-FXIRx, an antisense therapeutic designed to reduce the production of Factor XI for the prevention of thrombosis. ... Licence, collaboration. 237.5. Portola
This month GSK elected not to currently proceed with its option to Ionis Pharmaceuticals' IONIS-TTRrx, which was about to enter into phase 3 clinical development. ... The knock on effect for Ionis shares was a dip by a significant 40%.
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...